- 期刊
The Efficacy of Nebulized Beta-2 Agonist Bronchodilator Therapy in the Treatment of Acute Bronchiolitis
噴霧式支氣管擴張劑在治療急性細支氣管炎之評估
摘要
急性細支氣管炎為嬰幼兒常見之下呼吸道疾病，引起急性下呼吸道阻塞，常造成急性呼吸因難之症狀。為評估經由面罩噴霧式投與乙二型交感視經支氣管擴張劑(Terbutaline)之療效，在於支氣管收縮急性細抜氣管炎病人所扮演的角色;我們收集了38位病人，分成2組:第一組為治療組，第二組為安慰劑組。我們發現全部病人在呼吸速率、心跳、使用副肌肉分數(accessory muscle score)、哮鳴分數(wheeze score)、血氧飽和及呼氣末二氧化碳度變化，均有改善的現象。尤其在第二夾狀改善特別明顯。但二組之間在第二天的治療效果並無統計學上意義。此驗指出臨床常用於急性細抜管炎的乙二型交感視經支氣管擴張劑的噴霧療法並無臨床上的明顯意義。所以治療上還需傳統休守療法，如給予濕冷氧氣的環境以減緩低血氧及呼吸過速所造成之不可見水喪失。因此，在嬰幼兒急性支質管炎時，給予乙型交感神經擴張劑並非必要之處理。(慈濟醫學1998;10:95-101)
並列摘要
Acute bronchiolitis is a common lower respiratory tract infections in infants and toddlers less than 3 years old. In order to evaluate the effectiveness of the nebulized beta-2 agonist bronchodilator, Terbutaline, in the treatment of acute bronchiolitis, we collected thirty-eight young children suffering from acute bronchiolitis and divided them into a treatment group and a placebo group. Clinical data on respiratory rate, heart rate, accessory muscles motor score, wheezing score and the oxygen saturation and end-tidal carbon dioxide concentration were recorded in all patients before and after treatment. Both groups improved after treatment, especially on the second day without obvious side effects. We concluded that the nebulized beta-2 agonist bronchodilator, Terbutaline, does not produce a clinical benefit superior to placebo in the treatment of bronchiolitis.(Tzu Chi Med J1998;10:95-101)